Competitive Edge: Codexis, Inc.

Q: What was the reason for founding your organization – what was the open niche you saw that could be addressed with a new product or service? What was the problem, or gap, or opportunity?

Codexis works to create a brighter future by improving the health of people, and our planet. By discovering, developing and commercializing novel enzymes, we improve manufacturing efficiency with biocatalytic cascades, replacing chemical processes with enzymatic ones. The global API market was valued at $135.4bn in 2020.

Q: Tell us about your organization. What do you do?

Our novel enzymes enable sustainable processes in API manufacturing and in other areas such as food ingredient manufacturing, biomaterials, and consumer care to increase yield and/or reduce cost and waste.

Q: What stage of development are you?

Commercial stage – have mature products or services on the market.

Q: What do your technologies, products or services do and accomplish – how does it (they) work, who is it (they) aimed for?

Codexis is a leading enzyme engineering company that applies its proprietary CodeEvolver® technology to develop products for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.

Q: Competitively, what gives your technology, product or service set an edge in cost or performance, sustainability, or any other aspect, that makes it stand out from the crowd, In short, what makes it transformative?

Codexis is committed to enabling efficient and sustainable processes in manufacturing which can be achieved using an enzymatic approach and biocatalytic cascades instead of chemicals. Chemical processes can be inefficient and wasteful; biocatalytic processes using natural enzymes often can be complex with low yield. Our engineered enzymes enable effective biocatalytic processes that deliver performance and reduce cost.

Q: What are the 3 top milestones you have accomplished in the past 3 years?

1. 1. Sales to 21 of the top 25 pharmaceutical companies
2. 2. 11 commercial installations in API synthesis
3. 3. Novel enzyme cascade commercialized in the food industry

Q: What are the 3 top milestones you will accomplish in the next 3 years?

1. 1. Educate the market about the benefits of enzymatic processes
2. 2. Increase adaptation of sustainable manufacturing processes
3. 3. Help our customers improve the triple bottom line – social, environmental and financial

Q. Where can I learn more about Codexis Inc.?

Click here to visit Codexis Inc.’s website.